FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is liquid composition of elsamitrucin for treatment of tumorour diseases or conditions, including: a) at least one stable salt of elsamitrucin, which represents product of free elsamitrucin base and organic acid and can exist as stable solid substance and does not include pseudo-salts or salts, obtained in situ, which exist only in solution, and b) pharmaceutically acceptable carrier, and claimed liquid composition does not contain antioxidants or methanol, ethanol, chloroform, n-butanol or t-butanol as admixtures, and claimed stable salt of elsamitrucin preserves at least 90% of its anti-tumor activity within 18 months in liquid form at appropriate storage temperature.
EFFECT: it is shown, that compositions, namely disclosed in claimed invention water solutions of true elsamitrucin salts, can be preserved and introduced without reduction before application.
16 cl, 7 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SALTS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASE | 2013 |
|
RU2711077C2 |
| ALBUMIN-BINDING PRODRUGS BASED ON AURISTATIN E DERIVATIVES | 2018 |
|
RU2795101C2 |
| PHARMACEUTICAL COMPOSITIONS OF SAPOSIN C AND METHODS FOR TREATING CANCER | 2018 |
|
RU2767199C1 |
| PREPARATIVE FORM OF ARGATROBAN | 2006 |
|
RU2416393C2 |
| LIPOSOMAL COMPOSITION | 2010 |
|
RU2476216C1 |
| METHODS OF PRODUCTION ISOQUINOLINONES AND SOLID FORMS ISOQUINOLINONES | 2012 |
|
RU2626883C2 |
| SOLID FORMS OF CEFTOLOZANE | 2014 |
|
RU2703457C2 |
| ANTITUMOUR ANTHRAFURANDIONE AND BASED PHARMACEUTICAL COMPOSITIONS | 2014 |
|
RU2554939C1 |
| CONTINUOUS ADMINISTRATION OF L-DOPA, INHIBITORS OF DOPA-DECARBOXYLASE, INHIBITORS OF CATECHOL-O-METHYLTRANSFERASE AND COMPOSITIONS, INTENDED FOR IT | 2011 |
|
RU2607497C2 |
| POLYMORPHS OF 2-(4-(2-(1-ISOPROPYL-3-METHYL-1H-1,2,4-TRIAZOL-5-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPANAMIDE, METHODS OF PRODUCTION AND PHARMACEUTICAL USES THEREOF | 2014 |
|
RU2658009C2 |
